Latest:
Dr Vincelette on MYC Expression in Myelofibrosis
Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sai Yendamuri, MD, FACS
Latest:
Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer
Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.
Tillman Nechtman, PhD
Tillman W. Nechtman is Professor and Chair of the Department of History at Skidmore College, New York. He is also a lung cancer widower and a committed patient advocate working to advance lung cancer research.
Latest:
Vulnerable Conversations Contribute to Patient Advocacy Efforts to Propel Lung Cancer Research: With D. Ross Camidge, MD, PhD; and Tillman Nechtman, PhD
Drs Camidge and Nechtman discuss Dr Nechtman's experience supporting and caring for his wife Laura during her lung cancer diagnosis and treatment.
Yardlee Kauffman
Latest:
Integrating New Standards for Metastatic HER2+ Breast Cancer
The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.
Sherise Rogers, MD, MPH
Latest:
Dr Rogers on the NEO-Nal-IRI Trial in Pancreatic Adenocarcinoma
Sherise Rogers, MD, MPH, discusses the rationale for investigating irinotecan liposome injection plus 5-fluorouracil, leucovorin, and oxaliplatin in the preoperative treatment of patients with pancreatic adenocarcinoma.